Promethera Biosciences has increased its series D round to $44.4m with a $33.1m Mitsui and Medipal-backed extension, adding to Itochu’s initial investment earlier this year.

Belgium-based liver disease therapy developer Promethera Biosciences closed its series D round at €39.7m ($44.4m) yesterday following a $33.1m extension that included corporates Mitsui and Medipal Holdings. Diversified conglomerate Mitsui and medical supplies producer Medipal Holdings were joined in the second tranche by financial services firm Mirae Asset Capital, Six Snow, Korea Investment Partners and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.